Merrimack Pharmaceuticals Inc (MACK) - News Archive

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) has recently received stockholder approval for its Plan of Dissolution and subsequently declared a cash liquidating dividend of $15.10 per share. The company s Common Stock...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a renowned biopharmaceutical company based in Cambridge, MA, recently announced that its stockholders have overwhelmingly approved the adoption of a Plan of Dissolution. F...

In a recent announcement, Merrimack Pharmaceuticals, Inc. declared that its stockholders have overwhelmingly approved a Plan of Dissolution, marking a significant development for the company. Alongside this approval, th...